Her2 Testing recommendations in Australia
2001; Elsevier BV; Volume: 33; Issue: 4 Linguagem: Inglês
10.1080/00313020120083133
ISSN1465-3931
AutoresMichael Bilous, Colin J. Ades, Jane E. Armes, Richard H. Bell, Robert W. Brown, Bridget Cook, Margaret C. Cummings, Andrew Field, Huw Llewellyn, Paul McKenzie, Wendy A. Raymond, Peter Robbins, Lisa Tan,
Tópico(s)Glycosylation and Glycoproteins Research
ResumoHER2 is the target of a new treatment for metastatic breast cancer using the humanised monoclonal antibody trastuzumab (Herceptin). Since only around 20% of breast cancers carry the overexpressed HER2 receptor protein to which this treatment is directed, patient selection is very important in determining eligibility for the drug. Currently, immunohistochemistry and fluorescence in situ hybridisation are the main tests used for HER2 detection, and these testing recommendations have been developed based on national and international data.
Referência(s)